Search Result

Isoforms Recommended:	MLCK

Results for "

MLCK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ASK1 (1) Autophagy (1) Calmodulin (3) CaMK (3) Casein Kinase (1) COX (1) FAK (1) Interleukin Related (3) Myosin (16) Na+/K+ ATPase (1) NF-κB (2) NOD-like Receptor (NLR) (2) Phosphodiesterase (PDE) (1) PKA (5) PKC (4) Reference Standards (2) ROCK (3) Small Interfering RNA (siRNA) (6) TNF Receptor (1) YAP (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (1) Inflammation/Immunology (2) Metabolic Disease (4) Neurological Disease (4)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (3) siRNAs (6)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15417

ML-7 hydrochloride Maximum Cited Publications 24 Publications Verification	Myosin YAP	Cancer
ML-7 hydrochloride is a naphthalene sulphonamide derivative, potently inhibits *MLCK* (IC₅₀=300 nM). ML-7 hydrochloride also inhibits YAP/TAZ.

HY-100932

ML-9 5 Publications Verification	Myosin	Cancer
ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 inhibits inhibits MLCK, PKA and PKC activity with K_i values of 4, 32 and 54 μM, respectively . ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation .

HY-18271

CaMKII-IN-1 5 Publications Verification	CaMK	Neurological Disease
CaMKII-IN-1 is a highly selective inhibitor of CaMKII with an IC50 value of 63nM. It has almost no effect on CaMKIV, MLCK, p38a, Akt1, and PKC.

HY-100984

HA-100 1 Publications Verification	PKA PKC Myosin ROCK	Cancer
HA-100 is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK inhibitor .

HY-P5523A

iE-DAP dihydrochloride	NOD-like Receptor (NLR) NF-κB Interleukin Related	Metabolic Disease
iE-DAP dihydrochloride is a Nod1 agonist. iE-DAP dihydrochloride activates NOD1, which in turn activates the NF-κB signaling pathway and *MLCK* signaling pathway, inducing cellular inflammatory responses and tight junction disruption. iE-DAP dihydrochloride downregulates the expression of ZO-1 and Occludin genes. iE-DAP dihydrochloride increases the secretion of IL-6, GRO-α, MCP-1, IL-8 and MIP-1β in term human trophoblast cell cultures. iE-DAP dihydrochloride triggers preterm birth in pregnant mice, reduces fetal body weight, and induces fetal inflammation. iE-DAP dihydrochloride can be used in studies related to mastitis and preterm birth .

HY-P1029

MLCK inhibitor peptide 18 5+ Cited Publications	Myosin CaMK Autophagy	Others
MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC₅₀ of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.

HY-P1805

Calmodulin Binding Peptide 1	Calmodulin	Neurological Disease
Calmodulin Binding Peptide 1 is a high-affinity (pM) CaM-binding peptide derived from smooth muscle myosin light chain kinase (MLCK peptide). The interface of the complex formed by Calmodulin Binding Peptide 1 and Ca ²⁺-CaM can be specifically bound by small-molecule inhibitors, serving as a key target for selective regulation of smooth muscle contraction and development of anti-CaM drugs .

HY-P3965

16-38-Thymosin β4 (cattle)	Myosin	Neurological Disease
16-38-Thymosin β4 (cattle) is a Ca ²⁺-independent *MLCK* activator with high affinity .

HY-120997

E6 Berbamine Berbamine p-nitrobenzoate	Calmodulin Myosin Phosphodiesterase (PDE)	Cardiovascular Disease Cancer
E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activities of calmodulin-dependent myosin light chain kinase (MLCK) and phosphodiesterase (PDE). E6 Berbamine exhibits anti-leukemic activity. E6 Berbamine can be used in research related to cardiovascular abnormalities and chronic myeloid leukemia .

HY-169183

Myokinasib-II	Myosin	Cancer
Myokinasib-II is a myosin light chain kinase (MLCK) inhibitor, which is a potential target for inflammatory diseases, cancer and other diseases. .

HY-P5523

iE-DAP	NOD-like Receptor (NLR) NF-κB Interleukin Related	Metabolic Disease
iE-DAP is a Nod1 agonist. iE-DAP activates NOD1, which in turn activates the NF-κB signaling pathway and MLCK signaling pathway, inducing cellular inflammatory responses and tight junction disruption. iE-DAP downregulates the expression of ZO-1 and Occludin genes. iE-DAP increases the secretion of IL-6, GRO-α, MCP-1, IL-8 and MIP-1β in term human trophoblast cell cultures. iE-DAP triggers preterm birth in pregnant mice, reduces fetal body weight, and induces fetal inflammation. iE-DAP is applicable to research related to mastitis and preterm birth .

HY-P2162

Kemptamide	Myosin	Cancer
Kemptamide, a 13 amino acid fragment with a sequence corresponding to residues 11-23 of gizzard light chain. Kemptamide is a peptide substrate of myosin light-chain kinase (MLCK) .

HY-125957

A-3 hydrochloride	PKA Casein Kinase CaMK PKC	Others
A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (K_i=4.3 µM), casein kinase II (K_i=5.1 µM) and myosin light chain kinase (MLCK) (K_i=7.4 µM). A-3 hydrochloride also inhibits PKC and casein kinase I with K_i values of 47 µM and 80 µM, respectively .

HY-100932A

ML-9 Free Base	Myosin	Cancer
ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with K_i values of 4, 32 and 54 μM, respectively . ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation .

HY-19133

ME 3407 EF-4040	Na+/K+ ATPase Myosin PKA	Metabolic Disease
ME-3407 (EF-4040) is a H ⁺-K ⁺-ATPase redistribution disruptor and myosin light chain kinase (MLCK) and protein kinase A inhibitor. ME-3407 blocks gastric acid secretion and aminopyrine accumulation by inhibiting microsomal-to-apical membrane redistribution of H ⁺-K ⁺-ATPase and suppressing MLCK-mediated myosin light chain phosphorylation. ME-3407 is promising for research of peptic ulcer .

HY-P10165

MLCK Peptide	Calmodulin	Metabolic Disease
MLCK Peptide is a fully reversible, high affinity (pM) CaM-binding peptide derived from smooth muscle myosin light-chain kinase .

HY-RS29175

Mylk3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mylk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mylk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mylk3 Rat Pre-designed siRNA Set A Mylk3 Rat Pre-designed siRNA Set A

HY-RS22661

Mylk3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mylk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mylk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mylk3 Mouse Pre-designed siRNA Set A Mylk3 Mouse Pre-designed siRNA Set A

HY-RS08925

MYLK3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MYLK3 Human Pre-designed siRNA Set A contains three designed siRNAs for MYLK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MYLK3 Human Pre-designed siRNA Set A MYLK3 Human Pre-designed siRNA Set A

HY-P3965A

16-38-Thymosin β4 (cattle) TFA	Myosin	Neurological Disease
16-38-Thymosin β4 (cattle) TFA is a Ca ²⁺-independent *MLCK* activator with high affinity .

HY-P5998

Myosin Light Chain Kinase Substrate (smooth muscle)	Myosin	Cancer
Myosin Light Chain Kinase Substrate (smooth muscle) is a smooth muscle myosin light chain kinase (MLCK) synthetic peptide substrate .

HY-RS08924

MYLK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MYLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for MYLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MYLK2 Human Pre-designed siRNA Set A MYLK2 Human Pre-designed siRNA Set A

HY-100984A

HA-100 hydrochloride	PKA PKC Myosin ROCK	Cancer
HA-100 hydrochloride is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a ROCK inhibitor .

HY-RS18624

Mylk Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mylk Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mylk gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mylk Mouse Pre-designed siRNA Set A Mylk Mouse Pre-designed siRNA Set A

HY-176882

ASK1-IN-11	ASK1 TNF Receptor	Inflammation/Immunology
ASK1-IN-11 (Compound 7) is an apoptosis signal-regulating kinase 1 (ASK1) inhibitor with an IC₅₀ <200 nM. ASK1-IN-11 also shows inhibitory activities to TNF-α, MYLK/MLCK Kinase and hERG potassium channels . ASK1-IN-11 can be used for the research of inflammation .

HY-RS08923

MYLK Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MYLK Human Pre-designed siRNA Set A contains three designed siRNAs for MYLK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MYLK Human Pre-designed siRNA Set A MYLK Human Pre-designed siRNA Set A

HY-13692

1α-Hydroxyvitamin D5 CARD-024	Myosin FAK Interleukin Related COX	Inflammation/Immunology
1α-Hydroxyvitamin D5 (CARD-024) is a vitamin D analog with extremely low hypercalcemic effects. 1α-Hydroxyvitamin D5 effectively attenuates the pro-fibrotic response of colonic myofibroblasts to TGFβ and high-stiffness substrates by inhibiting the expression of αSMA, the phosphorylation of FAK, and the gene expression of *MLCK* and ET-1, while activating the anti-inflammatory pathway of IL-1β/COX-2. 1α-Hydroxyvitamin D5 can be used in research related to intestinal fibrosis associated with Crohn's disease .

HY-100932R

ML-9 (Standard)	Myosin Reference Standards	Cancer
ML-9 (Standard) is the analytical standard of ML-9 (HY-100932). This product is intended for research and analytical applications. ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation .

HY-100984R

HA-100 (Standard)	PKA Reference Standards PKC Myosin ROCK	Cancer
HA-100 (Standard) is the analytical standard of HA-100 (HY-100984). This product is intended for research and analytical applications. HA-100 is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK inhibitor .

Cat. No.	Product Name	Target	Research Area

HY-P5523A

iE-DAP dihydrochloride	NOD-like Receptor (NLR) NF-κB Interleukin Related	Metabolic Disease
iE-DAP dihydrochloride is a Nod1 agonist. iE-DAP dihydrochloride activates NOD1, which in turn activates the NF-κB signaling pathway and *MLCK* signaling pathway, inducing cellular inflammatory responses and tight junction disruption. iE-DAP dihydrochloride downregulates the expression of ZO-1 and Occludin genes. iE-DAP dihydrochloride increases the secretion of IL-6, GRO-α, MCP-1, IL-8 and MIP-1β in term human trophoblast cell cultures. iE-DAP dihydrochloride triggers preterm birth in pregnant mice, reduces fetal body weight, and induces fetal inflammation. iE-DAP dihydrochloride can be used in studies related to mastitis and preterm birth .

HY-P1029

MLCK inhibitor peptide 18 5+ Cited Publications	Myosin CaMK Autophagy	Others
MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC₅₀ of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.

HY-P1805

Calmodulin Binding Peptide 1	Calmodulin	Neurological Disease
Calmodulin Binding Peptide 1 is a high-affinity (pM) CaM-binding peptide derived from smooth muscle myosin light chain kinase (MLCK peptide). The interface of the complex formed by Calmodulin Binding Peptide 1 and Ca ²⁺-CaM can be specifically bound by small-molecule inhibitors, serving as a key target for selective regulation of smooth muscle contraction and development of anti-CaM drugs .

HY-P3965

16-38-Thymosin β4 (cattle)	Myosin	Neurological Disease
16-38-Thymosin β4 (cattle) is a Ca ²⁺-independent *MLCK* activator with high affinity .

HY-P3214

Myosin light chain kinase fragment 11-19 amide MLCK(11-19) amide	Peptides	Cancer
Myosin light chain kinase fragment 11-19 amide (MLCK(11-19) amide) is a substrate-specific peptide inhibitor of MLCK. Myosin light chain kinase fragment 11-19 amide inhibits hypotonicity-induced Ca ²⁺ entry. Myosin light chain kinase fragment 11-19 amide can be used in the research of human cervical cancer .

HY-P5523

iE-DAP	NOD-like Receptor (NLR) NF-κB Interleukin Related	Metabolic Disease
iE-DAP is a Nod1 agonist. iE-DAP activates NOD1, which in turn activates the NF-κB signaling pathway and MLCK signaling pathway, inducing cellular inflammatory responses and tight junction disruption. iE-DAP downregulates the expression of ZO-1 and Occludin genes. iE-DAP increases the secretion of IL-6, GRO-α, MCP-1, IL-8 and MIP-1β in term human trophoblast cell cultures. iE-DAP triggers preterm birth in pregnant mice, reduces fetal body weight, and induces fetal inflammation. iE-DAP is applicable to research related to mastitis and preterm birth .

HY-P2162

Kemptamide	Myosin	Cancer
Kemptamide, a 13 amino acid fragment with a sequence corresponding to residues 11-23 of gizzard light chain. Kemptamide is a peptide substrate of myosin light-chain kinase (MLCK) .

HY-P10165

MLCK Peptide	Calmodulin	Metabolic Disease
MLCK Peptide is a fully reversible, high affinity (pM) CaM-binding peptide derived from smooth muscle myosin light-chain kinase .

HY-P5436

*SK-MLCK* M13**	Peptides	Others
SK-MLCK M13 is a biological active peptide. (M-13 is a peptide that represents CAM-binding domain of Calmodulin (CaM) target proteins. CaM is an ubiquitous Ca2+ binding protein.)

HY-P3965A

16-38-Thymosin β4 (cattle) TFA	Myosin	Neurological Disease
16-38-Thymosin β4 (cattle) TFA is a Ca ²⁺-independent *MLCK* activator with high affinity .

HY-P5998

Myosin Light Chain Kinase Substrate (smooth muscle)	Myosin	Cancer
Myosin Light Chain Kinase Substrate (smooth muscle) is a smooth muscle myosin light chain kinase (MLCK) synthetic peptide substrate .

HY-P10166

MLCK Peptide, control	Peptides	Others
MLCK Peptide, control is a myosin light-chain kinase. Adding MLCK peptide to permeabilized L15 cells dramatically decreased IICR. MLCK peptide caused a reduction in the extent of IICR with no change in the affinity of IP3 for the IP3R .

Recombinant Proteins Recommended:

MLCK

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703167

	MYLK Protein, Human (Inactive, sf9, His, GST) MLCK1; MLCK; MYLK1	Human	Sf9 insect cells
	MYLK Protein, Human (Inactive, sf9, His, GST) is the recombinant human-derived MYLK, expressed by sf9 insect cells , with His, GST labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (2) Rabbit (2)
Reactivity:	Human (4) Rat (2) Mouse (4)
Application:	IHC-P (4) ICC/IF (4) WB (4) FC (4) ELISA (2)
Isotype:	IgG (2) IgG1 (2)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84598

	*Myosin light chain kinase/MLCK* Antibody (YA4295)** KRP; AAT7; MLCK; MLCK1; MMIHS; MYLK1; smMLCK; MLCK108; MLCK210; MSTP083	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse
	Myosin light chain kinase/MLCK Antibody (YA4295) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Myosin light chain kinase/MLCK.

HY-P84598A

	*Myosin light chain kinase/MLCK* Antibody (YA4295)(PBS only)** KRP; AAT7; MLCK; MLCK1; MMIHS; MYLK1; smMLCK; MLCK108; MLCK210; MSTP083	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse
	Myosin light chain kinase/MLCK Antibody (YA4295) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Myosin light chain kinase/MLCK.

HY-P83388

	*Myosin light chain kinase/MLCK* Antibody (YA3133)** KMLS; KRP; MLCK; MYLK; myosin light chain kinase; smooth muscle and non-muscle isozymes; myosin light polypeptide kinase; telokin	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	Myosin light chain kinase/MLCK Antibody (YA3133) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Myosin light chain kinase/MLCK.

HY-P80236

	*Myosin light chain kinase/MLCK* Antibody (YA277)**	WB, ICC/IF, IHC-P, FC	Human, Mouse, Rat
	Myosin light chain kinase/MLCK Antibody (YA277) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Myosin light chain kinase/MLCK.